Abivax SA Sponsored ADR
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Abivax SA Sponsored ADR is a biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to help stabilize the immune response in chronic inflammatory diseases. The company’s lead program centers on obefazimod, a clinical-stage candidate being studied for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. Abivax SA Sponsored ADR operates as a sponsored American Depositary Receipt representing the company’s ordinary shares, giving U.S. investors access to a France-based biopharmaceutical developer. Its current work is centered on clinical research, drug development, and advancing treatments aimed at complex immune-mediated conditions. Based in Paris, Abivax SA remains positioned within the global biotechnology market as a specialist in immunology-focused therapies and late-stage clinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Marc M. P. de Garidel M.B.A.
- Employees
- 98
- Headquarters
- Paris, France
- Website
- www.abivax.com